Eton Pharmaceuticals shocks investors with major acquisition: Shares explode to 52-week high
Eton Pharmaceuticals has sent shockwaves through the pharmaceutical industry after its shares soared to a 52-week high, fueled by the acquisition of the critical rare disease treatment Increlex. The stock surged to $6.08, marking a pinnacle in a year filled with strategic moves and bold acquisitions. This dramatic rise in stock value is driven by […]